R. Kiarash

发表

Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress.

B. Faubert, Russell G. Jones, S. Berger, 2011, Genes & development.

Penetration and intracellular routing of nucleus-directed peptide-based shuttles (loligomers) in eukaryotic cells.

J. Gariépy, R. Kiarash, K. Kawamura, 1998, Biochemistry.

Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In

R. Reilly, R. Kiarash, P. Maiti, 2001, Nuclear medicine communications.

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.

Narendra Kumar Patel, Y. Liu, T. Mak, 2016, ACS medicinal chemistry letters.

The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.

Narendra Kumar Patel, Y. Liu, T. Mak, 2015, Journal of medicinal chemistry.

Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.

Narendra Kumar Patel, T. Mak, N. Chirgadze, 2014, Bioorganic & medicinal chemistry.

The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

Narendra Kumar Patel, T. Mak, N. Chirgadze, 2015 .

Indium-11 Labelled Epidermal Growth Factor is Selectively Radiotoxic to Human Breast Cancer Cells Overexpressing the Epidermal Growth Factor Receptor

R. Hill, R. Cameron, R. Reilly, 2022 .

The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER+ breast cancer with mitotic aberrations

Benjamin Haibe-Kains, D. Cescon, K. Thu, 2022, Science advances.

The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.

Y. Liu, T. Mak, P. Sampson, 2013, Journal of medicinal chemistry.

The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

Narendra Kumar Patel, Y. Liu, T. Mak, 2015, Journal of medicinal chemistry.

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.

J. Gariépy, R. Cameron, R. Reilly, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.

J. Gariépy, R. Hill, R. Cameron, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.

Y. Liu, T. Mak, O. Plotnikova, 2016, Bioorganic & medicinal chemistry letters.

An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo

J. Gariépy, R. Kiarash, Xin Wei, 2010, Molecular Cancer.

The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

Narendra Kumar Patel, Y. Liu, T. Mak, 2015, Journal of medicinal chemistry.

Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.

D. Cescon, T. Mak, D. Awrey, 2014, Cancer cell.

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer

T. Mak, I. Beletskaya, M. Bray, 2017, Proceedings of the National Academy of Sciences.

Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.

Narendra Kumar Patel, T. Mak, P. Sampson, 2016, Bioorganic & medicinal chemistry letters.

Abstract 1642: Evaluation of ENMD-2076 in combination with anti-PD1 in syngeneic cancer models

M. Bray, R. Kiarash, G. Fletcher, 2017 .

The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

Narendra Kumar Patel, Y. Liu, T. Mak, 2015, Journal of medicinal chemistry.